AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
176.54
-1.47 (-0.83%)
Dec 30, 2024, 12:41 PM EST - Market open
| Period Ending | Sep 29, 2024 | Jun 29, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 29, 2023 | Mar 30, 2023 | Dec 31, 2022 | Sep 29, 2022 | Jun 29, 2022 | Mar 30, 2022 | Dec 31, 2021 | Sep 29, 2021 | Jun 29, 2021 | Mar 30, 2021 | Dec 31, 2020 | Sep 29, 2020 | Jun 29, 2020 | Mar 30, 2020 | Dec 31, 2019 | Sep 29, 2019 | Jun 29, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunology | 26.34B | 26.08B | 25.92B | 26.14B | 27.11B | 27.98B | 28.37B | 28.92B | ||||||||||||||
| Immunology Growth | -2.83% | -6.78% | -8.64% | -9.64% | -2.30% | 4.51% | 10.47% | 14.40% | ||||||||||||||
| Neuroscience | 8.58B | 8.26B | 7.99B | 7.72B | 7.33B | 6.96B | 6.74B | 6.53B | ||||||||||||||
| Neuroscience Growth | 17.06% | 18.70% | 18.59% | 18.21% | 13.30% | 9.36% | 9.21% | 10.14% | ||||||||||||||
| Hematologic Oncology | 6.37B | 6.20B | 6.04B | 5.92B | 6.04B | 6.18B | 6.35B | 6.58B | ||||||||||||||
| Hematologic Oncology Growth | 5.57% | 0.37% | -4.81% | -10.07% | -11.47% | -12.22% | -11.86% | -9.01% | ||||||||||||||
| Aesthetics | 5.25B | 5.25B | 5.24B | 5.29B | 5.21B | 5.27B | 5.26B | 5.33B | ||||||||||||||
| Aesthetics Growth | 0.75% | -0.44% | -0.30% | -0.73% | -4.46% | -2.42% | -3.79% | 1.91% | ||||||||||||||
| Other Products | 3.70B | 3.79B | 3.78B | 3.81B | 3.82B | 3.85B | 3.88B | 3.85B | ||||||||||||||
| Other Products Growth | -3.14% | -1.51% | -2.50% | -1.25% | -11.01% | -17.57% | -23.74% | -29.79% | ||||||||||||||
| Eye Care | 2.18B | 2.26B | 2.35B | 2.42B | 2.42B | 2.44B | 2.54B | 2.70B | ||||||||||||||
| Eye Care Growth | -9.88% | -7.26% | -7.60% | -10.59% | -21.20% | -26.54% | -27.92% | -24.28% |
Revenue by Geography
| Period Ending | Sep 29, 2024 | Jun 29, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 29, 2023 | Mar 30, 2023 | Dec 31, 2022 | Sep 29, 2022 | Jun 29, 2022 | Mar 30, 2022 | Dec 31, 2021 | Sep 29, 2021 | Jun 29, 2021 | Mar 30, 2021 | Dec 31, 2020 | Sep 29, 2020 | Jun 29, 2020 | Mar 30, 2020 | Dec 31, 2019 | Sep 29, 2019 | Jun 29, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| US | 42.41B | 42.11B | 41.72B | 41.88B | 42.97B | 43.88B | 44.57B | 45.71B | ||||||||||||||
| US Growth | -1.30% | -4.03% | -6.38% | -8.38% | -4.94% | -1.87% | 0.96% | 5.16% | ||||||||||||||
| International | 13.13B | 12.89B | 12.68B | 12.44B | 12.17B | 12.15B | 12.18B | 12.34B | ||||||||||||||
| International Growth | 7.85% | 6.12% | 4.15% | 0.76% | -3.55% | -3.86% | -3.50% | -2.73% |
Operating Expense Breakdown
| Period Ending | Sep 29, 2024 | Jun 29, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 29, 2023 | Mar 30, 2023 | Dec 31, 2022 | Sep 29, 2022 | Jun 29, 2022 | Mar 30, 2022 | Dec 31, 2021 | Sep 29, 2021 | Jun 29, 2021 | Mar 30, 2021 | Dec 31, 2020 | Sep 29, 2020 | Jun 29, 2020 | Mar 30, 2020 | Dec 31, 2019 | Sep 29, 2019 | Jun 29, 2019 | Mar 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative | 14.09B | 13.26B | 13.15B | 12.87B | 13.10B | 13.03B | 15.17B | 15.26B | ||||||||||||||||
| Selling, General, and Administrative Growth | 7.59% | 1.76% | -13.34% | -15.65% | -13.29% | -12.46% | 20.09% | 23.57% | ||||||||||||||||
| Research and Development | 7.94B | 7.54B | 7.32B | 7.68B | 7.54B | 7.43B | 7.31B | 6.51B | ||||||||||||||||
| Research and Development Growth | 5.39% | 1.45% | 0.23% | 17.90% | 15.14% | 12.66% | 8.19% | -5.95% | ||||||||||||||||
| Acquired In-Process R&D | 1.47B | 1.45B | 792.00M | 778.00M | 739.00M | 713.00M | 702.00M | 697.00M | ||||||||||||||||
| Acquired In-Process R&D Growth | 98.24% | 103.23% | 12.82% | 11.62% | -13.97% | -41.61% | -35.24% | -37.99% | ||||||||||||||||
| Other | - | - | - | - | - | 49.00M | 46.00M | 56.00M | ||||||||||||||||
| Other Growth | - | - | - | - | - | -85.06% | - | - |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.